150 related articles for article (PubMed ID: 35314096)
1. A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases.
Dijksterhuis WPM; Kroese TE; Verhoeven RHA; van Rossum PSN; Mook S; Haj Mohammad N; Hulshof MCCM; Gisbertz SS; Ruurda JP; van Oijen MGH; van Hillegersberg R; van Laarhoven HWM
Eur J Surg Oncol; 2022 Sep; 48(9):1964-1971. PubMed ID: 35314096
[TBL] [Abstract][Full Text] [Related]
2. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
Cardona K; Zhou Q; Gönen M; Shah MA; Strong VE; Brennan MF; Coit DG
Ann Surg Oncol; 2013 Feb; 20(2):548-54. PubMed ID: 22941159
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
5. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
7. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
8. Serum Interleukin 6 Level is Associated With Overall Survival and Treatment Response in Gastric and Gastroesophageal Junction Cancer.
Karalis JD; Ju MR; Yoon LY; Castro-Dubon EC; Reznik SI; Hammer STG; Porembka MR; Wang SC
Ann Surg; 2023 Dec; 278(6):918-924. PubMed ID: 37450705
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
10. Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.
Grizzi G; Petrelli F; Di Bartolomeo M; Viti M; Texeira Moraes M; Luciani A; Passalacqua R; Ghidini M; Tomasello G; Baiocchi GL; Celotti A
Gastric Cancer; 2022 Sep; 25(5):982-987. PubMed ID: 35704113
[TBL] [Abstract][Full Text] [Related]
11. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?
Badgwell B; Cormier JN; Krishnan S; Yao J; Staerkel GA; Lupo PJ; Pisters PW; Feig B; Mansfield P
Ann Surg Oncol; 2008 Oct; 15(10):2684-91. PubMed ID: 18649106
[TBL] [Abstract][Full Text] [Related]
12. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
[TBL] [Abstract][Full Text] [Related]
13. Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma.
Ho F; Torphy RJ; Friedman C; Leong S; Kim S; Wani S; Schefter T; Scott CD; Mitchell JD; Weyant MJ; Meguid RA; Gleisner AL; Goodman KA; McCarter MD
Ann Surg Oncol; 2021 Nov; 28(12):7208-7218. PubMed ID: 33884489
[TBL] [Abstract][Full Text] [Related]
14. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
15. The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis.
Parry K; van Rossum PS; Haj Mohammad N; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2017 Jan; 43(1):226-233. PubMed ID: 27424786
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of Interval Distant Metastases After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Kroese TE; Dijksterhuis WPM; van Rossum PSN; Verhoeven RHA; Mook S; Haj Mohammad N; Hulshof MCCM; van Berge Henegouwen MI; van Oijen MGH; Ruurda JP; van Laarhoven HWM; van Hillegersberg R
Ann Thorac Surg; 2022 Feb; 113(2):482-490. PubMed ID: 33610543
[TBL] [Abstract][Full Text] [Related]
18. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.
Wu L; Xing Z; Huang M; Yu H; Qin Y; Jin Q; Zhou Z; Chen J
J Surg Oncol; 2022 Dec; 126(8):1403-1412. PubMed ID: 36001384
[TBL] [Abstract][Full Text] [Related]
19. Multimodal Therapy Versus Primary Surgery for Gastric and Gastroesophageal Junction Diffuse Type Carcinoma, with a Focus on Signet Ring Cell Carcinoma: A Nationwide Study.
Gertsen EC; van der Veen A; Brenkman HJF; Brosens LAA; van der Post RS; Verhoeven RHA; Luijten JCHBM; Vissers PAJ; Vegt E; van Hillegersberg R; Siersema PD; Ruurda JP
Ann Surg Oncol; 2024 Mar; 31(3):1760-1772. PubMed ID: 38127213
[TBL] [Abstract][Full Text] [Related]
20. Unanswered questions in the management of gastroesophageal junction adenocarcinoma: an overview from the medical oncologist's perspective.
Shah MA
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
